Variation and prognostic value of serum plasminogen activator inhibitor-1 before and after chemotherapy in patients with epithelial ovarian cancer.

Aim: The purpose of the present study was to explore variation and prognostic significance of serum plasminogen activator inhibitor-1 (PAI-1) before the first cycle of chemotherapy and after the sixth cycle of chemotherapy in epithelial ovarian cancer (EOC) patients who had undergone cytoreductive surgery.

Material And Methods: We retrospectively evaluated the serum PAI-1 level of EOC patients and healthy controls and investigated the correlation between both serum PAI-1 levels of EOC patients we detected and clinicopathological characteristics. Survival rates were analyzed by using the Kaplan-Meier technique and Cox regression model.